HCC immunotherapy takes effect mainly by activating immune checkpoints including programmed death-1 (PD-1), its ligand PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.